View Full Version : CHA: South Korean challenger

09-09-2015, 10:14 AM
Japan, S. Korea hospitals ink clinical pact on regenerative medicine
April 9, 2015 | By EJ Lane

"The operators of a pair of private hospital networks, one in Japan and the other in South Korea, signed a memorandum of understanding to cooperate on research into regenerative medicine, the work ranging from education activities to clinical applications.

The MOU was signed by the chairmen of Otsubo Medical of Japan and CHA Health systems of South Korea, each an operator of several private hospitals, according to Nikkei.
The two companies agreed to conduct joint clinical trials using induced pluripotent stem cells. CHA has already conducted clinical trials involving embryonic stem cells and has been working on iPS cell treatments.

A branch from CHA have hair as one of their major projects:
http://en.chabio.com/rd_chabio_lab.asp (scroll down)

CHA work with iPSCs, so it could be a solution like Terskish's process, but they also work on stemcells activators, hair cycle regulators

There's the names of the lead professors, I will try to find their mails to ask them about any clinical trials planned for a medication or stemcell treatment they work on, and about the recent progress on iPSC safety

09-09-2015, 10:23 AM
awesome find as always!

09-09-2015, 11:15 AM
Really becoming one of the best posters on here.

09-10-2015, 06:07 AM
Thanks for the link, lot of different attempts going on now, one will strike gold soon

09-11-2015, 04:09 AM
No answers from CHA bio lab for the moment

Another university from Korea talk about human placenta extract for hair growth as a new therapeutic strategy for hairloss. Not really exciting it's just a growth promoter but maybe it can work better than AAPE


2015 August 19

Human placental extract exerts hair growth-promoting effects through the GSK-3β signaling pathway in human dermal papilla cells.

Human placental extract (HPE) is widely used in Korea to relieve fatigue. However, its effects on human dermal papilla cells (hDPCs) remain unknown. In the present study, in an effort to develop novel therapies to promote hair growth, we screened HPE. We demonstrate that HPE has hair growth‑promoting activities and induces β‑catenin expression through the inhibition of glycogen synthase kinase‑3β (GSK‑3β) by phosphorylation in hDPCs. Treatment with HPE significantly increased the viability of the hDPCs in a concentration‑dependent manner, as shown by bromodeoxyuridine (BrdU) assay. HPE also significantly increased the alkaline phosphatase (ALP) expression levels.
Moreover, we demonstrated that HPE was effective in inducing root hair elongation in rat vibrissa hair follicles, and that treatment with HPE led to a delay in catagen progression. Overall, our findings suggest that HPE promotes hair growth and may thus provide the basis of a novel therapeutic strategy for the clinical treatment of hair loss.